anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Stroke is associated with a risk of epilepsy, but associations with age, sex, stroke type and severity, time trends, and mortality are uncertain. We studied the risk of epilepsy after stroke while accounting for sex, age, stroke types and severity, calendar time, and death.
METHODS: This was a prospective nationwide register-based, matched cohort study of patients admitted with a validated first stroke in Denmark from April 1, 2004, to December 16, 2018, excluding those with prior epilepsy. Patients with stroke were matched 10:1 on age, sex, and calendar time with reference people without prior epilepsy or stroke. We estimated the cumulative incidence of an epilepsy diagnosis in the Danish National Patient Registry (International Classification of Diseases Tenth Revision: G40) with death as a competing risk using competing risk regression and estimated adjusted hazard ratios by Cox regression models.
RESULTS: We identified 101 034 patients with stroke (46.5% female; mean age, 70.4 years) who survived 14 days after stroke along with 1 010 333 matched reference people. Two years after the stroke, the cumulative incidence of epilepsy was 3.0% (95% CI, 2.9-3.2) after ischemic stroke and 8.6% (95% CI, 8.0-9.2) after intracerebral hemorrhage versus 0.7% (95% CI, 0.7-0.7) in the matched references. Compared with the reference population, the 2-year hazard ratio of epilepsy was 21.7 (95% CI, 20.3-23.2) after ischemic stroke and 61.3 (95% CI, 51.1-73.4) after intracerebral hemorrhage. The risk of epilepsy increased with stroke severity; the 2-year cumulative incidence of epilepsy was 10.5% (95% CI, 9.5-11.4) for very severe ischemic stroke and 13.1% (95% CI, 11.1-15.1) after very severe intracerebral hemorrhage.
CONCLUSIONS: In this population-based study of patients with validated stroke, the absolute and relative risk estimates of poststroke epilepsy were lower compared with previous studies. Reasons for the lower risk estimates include accounting for the high mortality associated with stroke, which had a significant impact on risk especially for severe stroke.
To assist in selection of image data being a comparison object.SOLUTION: A medical image processing apparatus comprises: a designation unit; a selection unit; a first generation unit; a display control unit; and a second generation unit. The designation unit designates first image data. The selection unit selects one or a plurality of pieces of second image data from the plurality of image data sets having the plurality of pieces of image data. The first generation unit generates a difference image between the first image data and each of the one or the plurality of pieces of second image data. The display control unit displays a list image indicating the list of the difference images generated by the first generation unit. The second generation unit generates the difference image between the first image data and each of the plurality of pieces of image data of the image data set having the second image data that becomes the base of the difference image selected from the list image.SELECTED DRAWING: Figure 1
INTRODUCTION: Early-onset atrial fibrillation (AF) has already been observed in approximately 2% of patients with genetically proven long QT syndrome (LQTS). This frequency is higher than population-based estimates of early-onset AF. However, the concomitant expression of AF in LQTS is likely underestimated. The purpose of this study was to examine the clinical presentation, genetic background, and outcomes of a cohort of patients with LQTS and early-onset AF referred to a single tertiary center.
METHODS: Twenty-seven patients diagnosed with congenital LQTS were included in the study based on the documentation of early-onset (age ≤50 years) clinical or subclinical AF episodes in all available medical records, including standard electrocardiograms, wearable monitor or cardiac implantable electronic devices.
RESULTS: Seventeen patients experienced clinical AF during the follow-up period. Subclinical AF was detected in 10 patients through insertable or wearable cardiac monitors. In our series, the mean heart rate during AF episodes was found to be relatively low despite the patients' young age and the low or minimal effective doses of beta-blockers used for QTc interval control. All patients exhibiting LQTS and early-onset AF were genotype positive, carrying mutations in the KCNQ1 (66%), KCNH2, KCNE1, and SCN5A genes. Notably, most of these patients carried the same p.(R231C) mutation in the KCNQ1 gene (59%) and were from the same families, suggesting concurrent expression of familial AF and LQTS.
CONCLUSION: LQTS patients are prone to developing clinical and subclinical AF, even at a younger age. The occurrence of early-onset AF in the LQTS population could be more frequent than previously assumed. AF should be considered as a potential dysrhythmia related to LQTS. Our study emphasizes the importance of carefully researching clinical and/or subclinical episodes of AF through strict heart rhythm monitoring in the LQTS population.
A method for treatment of a disease by monitoring a progression of the disease includes obtaining image data including a representation of diseased cells of a patient. Based on the type of the disease, one or more features to extract from the image data are determined, the features each representing a physical parameter of at least one of the diseased cells represented in the image data. A feature vector is formed from the extracted features. A machine learning model is selected, and the feature vector is processed using the machine learning model. The machine learning model is trained with labeled image data representing instances of diseased cells having the disease and associating scores representing predicted rates of disease progression with the respective instances of diseased cells having the type of disease. Based on the processing, a score is determined that represents a predicted rate of disease progression indicated by the image data.
PROBLEM TO BE SOLVED: To obtain a foamable cosmetic with high cool or warm feeling effect which is sustainable as well, therefore useful as a cleansing cosmetic or the like by including a specific inorganic matter, a carbonate, and a cool or warm feeling agent. SOLUTION: This foamable cosmetic is obtained by including (A) pref. 10-50 wt.% of an acid solid at normal temperatures or an inorganic matter exhibiting acidity when dissolved in water (e.g. aluminum potassium sulfate), (B) pref. 10-50 wt.% of a carbonate such as sodium bicarbonate or sodium carbonate, and (C) pref. 0.1-50 wt.% of a cool feeling agent such as xylitol or a warm feeling agent such as polyethylene glycol, in the equivalent ratio A/B of pref. (1:5) to (5:1) in terms of acid and base.
An instant veterinary Chinese medicinal granule is prepared from raw material extract and adjuvants including dextrin, lactose and sucrose. Wherein the mass ratio of the extract is 15-25%, and the mass ratios of dextrin, lactose and sucrose are respectively 15-17%, 22-25% and 38-43%. The invention takes sucrose as a bonding agent and lactose and medical dextrin as a disintegrating agent. The purpose of quick dissolution can be achieved by utilizing the characteristic that sucrose and lactose are easy to dissolve in water, and the instant dissolution can be carried out at normal temperature. The sucrose can improve the bitter taste of the traditional Chinese medicine, and in addition, the lactose can promote the intestinal tract to rapidly wriggle, thereby promoting the absorption of effective components. The veterinary Chinese medicinal granules prepared by the invention are instant at normal temperature through scientific proportioning, comfortable in taste, easy to absorb and convenient to use.
Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, prostate cancer, renal carcinoma, small cell lung cancer (SCLC) and head-and-neck malignant tumor (HNMT).
Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
Improved compositions and methods for selective access to tumor regions (or other regions of abnormal endothelial properties). This capability provides powerful contrast-enhancement agents for nuclear magnetic resonance imaging. A polyatomic complex which includes intramolecular ferromagnetic coupling between metal atoms is associated with a polymer or microsphere carrier matrix which will bind to endothelial determinants. A solution containing this carrier complex is injected into a human (or other) body to be imaged. The carrier complex will preferentially extravasate at locations where the blood vessel walls have increased porosity or microvascular surface changes, and especially at tumor sites. Thus, the changes in relaxation time induced by the presence of the carrier complex will provide a high-gain marker for magnetic resonance imaging. 
     Multiple superparamagnetic polyatomic complexes are described, including novel complexes which include acetate and glycinate bridging ligands with a polyatomic metal-atom-complex core.
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) can influence pharmacokinetics. We investigated the vancomycin dosage in children on ECMO compared to critically ill children to determine the necessary dosage adjustment on ECMO.
METHODS: Eight-year, single-center, retrospective cohort study at a tertiary heart center's pediatric cardiac intensive care unit (ICU) of children undergoing ECMO support. Our control group (non-ECMO) was critically ill children with delayed sternal closure after cardiac surgery. We included consecutively all children undergoing vancomycin administration. The starting dose was 10 to 15 mg/kg BW per dose, every 8 to 12 hours depending on age. The vancomycin trough level was maintained in the 10 to 20 μg/ml range.
RESULTS: 85 total courses on ECMO and 99 non-ECMO courses were included. The ECMO group's daily vancomycin dose was significantly lower than non-ECMO's at a median of 33.3 and 38.5 mg/kg/d, respectively (p < 0.001). Vancomycin serum trough levels were similar between groups and within the target range. The ECMO group's daily vancomycin dose dropped faster over time, with a dose on day 3 of 28.7 and 33.7 mg/kg/d, respectively. The impact of renal function on vancomycin dosing was more apparent in the ECMO group. If the renal function was reduced at the start of treatment, the vancomycin dose was lower in the ECMO group compared to the non-ECMO group with renal impairment (22.5 vs. 42.1 mg/kg/d; p < 0.001). When renal function was normal, the doses were similar between groups.
CONCLUSION: In children on ECMO with impaired renal function at treatment initiation, lower vancomycin doses were necessary. Early therapeutic drug monitoring, even before reaching a steady state, should be considered.
The present invention relates to vesicles derived from Morganella sp. bacteria and a usage thereof. The inventors confirmed by experiments that the vesicles are meaningfully reduced in a clinical sample derived from patients suffering from malignant diseases of cancers of stomach, large intestine, pancreas, bile duct, breast, ovary, bladder, prostate and lymphoma, cardiovascular disorders such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, strokes and the like, diabetes and Parkinson′s diseases, compared with normal people, and the vesicles inhibit inflammatory mediator secretion by pathogenic vesicles while inhibiting cancer development in cancer animal models. According to the present invention, the vesicles derived from Morganella sp. bacteria may be useful for the purpose of developing a diagnosing method for preventing or treating malignant diseases of cancers of stomach, large intestine, pancreas, bile duct, breast, ovary, bladder, prostate and lymphoma, cardiovascular disorders such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, strokes and the like, diabetes and Parkinson′s diseases, and a composition for the diseases or inflammatory diseases. The present invention also relates to an information providing method for diagnosis which comprises: a step (a) of extracting DNA from vesicles separated from samples of a normal person and an examinee; a step (b) of obtaining PCR products by performing PCR on a pair of primaries with respect to the extracted DNA; and a step (c) of determining that the examinee has cancers in stomach, large intestine, pancreas, bile duct, breast, ovary, bladder, prostate and lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, strokes, diabetes or Parkinson′s diseases if contents of the vesicles derived from Morganella sp. bacteria of the examinee are less than those of the normal person.
Intermittent Theta Burst Stimulation (iTBS) will be applied to the left dorsolateral prefrontal cortex (DLPFC). Participants will receive daily sessions (Mon-Fri), three times a day for 10 days (2 weeks).
The invention discloses a medicated food for preventing and treating atherosclerosis. The medicated food is composed of the following raw materials in parts by weight: 500 to 1000 parts of crucian, 15 to 30 parts of red sage root, 5 to 10 parts of radix astragali, 5 to 10 parts of ginger, and 12 to 24 parts of jujube. The invention further discloses a preparation method and applications of the medicated food. The medicated food has the functions of boosting qi, activating blood, invigorating spleen, and tonifying kidney, is accord with the principle on treating atherosclerosis, and is capable of treating atherosclerosis effectively. The medicated food has a good effect during the preclinical phase of atherosclerosis, is capable of well preventing and treating coronary atherosclerotic cardiopathy, carotid atherosclerosis, renal atherosclerosis, and the like, and can be used to assist the therapy. The medicated food has the functions of boosting qi, activating blood, invigorating spleen, and tonifying kidney, has the advantages of fresh and delicious taste, rich nutrients, simple preparation, and low cost, is suitable for large-scale promotion and application, and has a good medical prospect.
Post-operative pain control is a key component of a patient's experience with surgery. In laparoscopic surgery, small (5 to 12mm) incisions are made, usually at the umbilicus and/on at either side of the lower abdomen, to allow insertion of a laparoscopic camera ("scope") and various laparoscopic instruments. The advantages for the patient of this approach compared to conventional open surgery include faster recovery with a significantly shorter hospital stay, less pain and less requirements for pain medication with a better cosmetic outcome. In many cases, the patient will go home within 24 hours of surgery. Many laparoscopic surgeons administer local anesthesia at the incision sites to assist in post-operative pain control. The best method for administration of the local anesthetic for optimal pain relief remains unclear. Some research has demonstrated that perhaps preemptive administration of local anesthetic improves post-operative pain control although in these studies, differences in patient populations and perception of pain between different patients makes comparison difficult. Optimizing analgesia protocols would benefit patients resulting in better pain relief and less use of narcotic analgesics with their associated side effects.
The invention discloses an amorphous calcium phosphate-polyacrylic acid hybrid nano material as well as a preparation method and application thereof, belonging to the field of biomedical materials. Under the synergistic stabilization effect of polyacrylic acid molecules and magnesium ions, the amorphous calcium phosphate-polyacrylic acid hybrid nano material is prepared by a wet chemical method. The doped polyacrylic acid molecules can complex calcium ions, and the calcium ions and the magnesium ions together hinder crystal generation. Compared with the existing calcium phosphate crystal material, the amorphous calcium phosphate-polyacrylic acid hybrid nano material has faster degradation and can be used for coating carriers of functional molecules such as genes, medicines and the like. For example, fluorescent molecules (e.g., fluorescein isothiocyanate, indocyanine green) can be coated in the hybrid material to achieve fluorescent imaging effect. Compared with the traditional fluorescence developing preparation, the amorphous calcium phosphate-polyacrylic acid hybrid nano material coats fluorescent molecules, has the function of quickly releasing the fluorescent molecules in a weak acid environment, and is a fluorescent carrier with excellent biocompatibility.
INTRODUCTION: In a French context of low vaccination coverage for human papillomavirus (HPV) disease, we conducted a study on pharmacy students and community pharmacists to assess their self-reported knowledge about HPV infection and vaccination and their perceptions of vaccination.
MATERIAL AND METHODS: A prospective volunteered-based study was conducted in the French Franche-Comté region based on a questionnaire targeting pharmacy students (from the 2nd to 6th years) and community pharmacists.
RESULTS: All in all, 220 students and 55 pharmacists completed a questionnaire. Fewer than a third knew which HPV genotypes are considered to be high-risk (p-value = 0.11) and were aware of the diversified nature of HPV-induced cancers (p-value = 0.02). Their overall level of general knowledge about vaccination was estimated to be good by 62% of students and 85% of pharmacists (p-value = 10-3). More than 75% of students and pharmacists considered that HPV vaccination has a positive benefit-risk balance (p-value = 0.44) but that its low coverage is due to non-confirmed adverse events that were suggested in the past (p-value = 0.60). Pharmacists had a better perception of the safety of HPV vaccination (84% versus 64%, p-value = 6·10-3). More than 50% of students and pharmacists agreed with mandatory HPV vaccination for girls and boys (11-14 years).
CONCLUSION: This study allowed us to assess the knowledge of students and community pharmacists and their more or less favorable perceptions of HPV vaccination. It helped us to suggest their needs in terms of practical training. Future changes should include pharmacists in the implementation of public health policies and to improve vaccination coverage.
Body dissatisfaction and eating behaviors are disproportionately elevated amongst adolescent girls. Family relationships represent a context in which adolescent girls' body image issues emerge. Thus, we integrated attachment and confirmation theories to examine whether weight related supportive messages (i.e., acceptance and challenge) mediated the relationship between attachment style (i.e., anxiety and avoidance) and body image outcomes (i.e., body dissatisfaction (BD), restrained eating (RE), and disordered eating (DE)). Acceptance refers to weight related support that is characterized by warmth and accepting messages; challenge refers to weight related support that is characterized by instrumental assistance and problem-solving messages. A sample of 106 adolescent girls, ages 11 to 21, completed self-report measures on attachment (Relationship Structures Questionnaire), acceptance and challenge (weight related Parental Behavior Questionnaire), body dissatisfaction (Eating Disorders Inventory), and eating behaviors (Dutch Eating Behavior Questionnaire; Eating Disorder Diagnostic Scale). Attachment anxiety directly related to all body image outcomes, whereas attachment avoidance only directly related to RE. Attachment avoidance only related to BD and DE indirectly through perceived acceptance. Those with high anxiety endorsed lower perceived challenge, whereas avoidant individuals endorsed lower perceived acceptance and challenge. We concluded that attachment dimension characteristics to be either hyperactivated regarding relationships (i.e., anxiety), or deactivated and distant (i.e., avoidance), are associated with how individuals perceive support, and in turn, are related to body image and eating behavior outcomes. Further, we clarify the differential roles of acceptance and challenge. Although both supportive, acceptance encompasses a layer of warmth that is more meaningful in body image, particularly for avoidantly attached individuals. By integrating qualities of attachment and supportive weight communication, we reveal that potential pathways of attachment to body image and eating behaviors.
PURPOSE:To form uniform coating by a reduced use amount of wax by selectively precipitating wax on the surface of a particle, by dissolving wax in a solvent mixture composed of an org. solvent and water, and immersing the particle becoming a core substance in the resulting solution. CONSTITUTION:Desired wax X such as fatty acid or higher alcohol is dissolved in a solvent mixture Y obtained by mixing an org. solvent such as ethanol or acetone and water and the formed solution is heated to 45 deg.C or less on a water bath. Next, this solution is injected in the particles 1 corresponding to a purpose such as food, medicines or feed and the particles 1 are immersed in said solution and rapidly stirred so as to uniformize the whole. By this method, since wax is precipitated on the surfaces of the particles 1, a slurry containing the particles 1 coated with wax is spray-dried and solvent removal treatment is applied to the particles 1 to obtain a mononuclear microcapsule Z1. Further, this microcapsule is subjected to melting, cooling and solidifying treatment to obtain a product Z2 having a densified surface.
The present invention provides a Chinese material medical preparation used for treating fracture and sore place and the means to make preparation. Calculated by weight share of raw material, the present invention is made by nux vomica plant of 45-55 shares, living Notoginseng 5-15 of shares, native copper 5-15 of shares, system breast of 2-8 shares, ground beetle of 5-15 shares, dragon's blood of 2-8 shares and four tile of 2-8 shares. Compared with the existing technology, the medical preparation of the present invention may take orally or externally. The present invention functions as blood circulation, removing extraverted blood. The present invention is capable of reducing swelling and alleviate pain quickly, improving the growth of osteotylus, recovering bone fracture shifting and reducing cicatrization time of bones. The present invention has obvious effect with little expense.